Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Delicate biogenerics dance

Following contentious discussions last week among senior managers of several member companies, the Biotechnology Industry Organization is finalizing the wording of a letter to FDA outlining its position about patent and trade secret issues associated with follow-on biologics.

The letter will endorse principles articulated by Genentech Inc. in a Citizen Petition filed in

Read the full 538 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE